Sign up to save your podcasts
Or
Share Vitiligo Drug FDA-Approved
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Vitiligo Drug FDA-Approved
Vidcast: https://youtu.be/LVnblQN2qkU
The FDA has approved ruxolitinib, the Janus kinase inhibitor, branded as Incyte’s Jakafi, effectively treats the auto-immune skin disease vitiligo that extinguishes natural skin color. The drug is now approved for all those 12 and older.
Jakafi mediated the return of a natural skin color in half of those using it. When effective, it mediated the return of 75% or more of facial pigment and 50% or more of pigment in all sites skin. Over 1/3 of adults and 50% of teens enjoyed cosmetically acceptable resolution of their vitiligo following a year of use.
https://www.webmd.com/skin-problems-and-treatments/news/20221024/cream-may-restore-skin-pigmentation-in-people-with-vitiligo?src=RSS_PUBLIC
#vitiligo #ruxolitinib #incyte #jakafi #autoimmune
View all episodes
By Howard G. Smith MD, AM
Vidcast: https://youtu.be/LVnblQN2qkU
The FDA has approved ruxolitinib, the Janus kinase inhibitor, branded as Incyte’s Jakafi, effectively treats the auto-immune skin disease vitiligo that extinguishes natural skin color. The drug is now approved for all those 12 and older.
Jakafi mediated the return of a natural skin color in half of those using it. When effective, it mediated the return of 75% or more of facial pigment and 50% or more of pigment in all sites skin. Over 1/3 of adults and 50% of teens enjoyed cosmetically acceptable resolution of their vitiligo following a year of use.
https://www.webmd.com/skin-problems-and-treatments/news/20221024/cream-may-restore-skin-pigmentation-in-people-with-vitiligo?src=RSS_PUBLIC
#vitiligo #ruxolitinib #incyte #jakafi #autoimmune